Scientists have developed a drug that targets both major aggregation-promoting sites of the Tau protein, a key player in ...
AG03, developed by researchers at the University of Southampton, targets two critical regions of the tau protein linked to ...
AG03, targets two key areas of the Tau protein in Alzheimer's disease, showing effectiveness in lab and fruit fly models.
An international team of researchers led by Lancaster University have made a promising breakthrough in the development of ...
Scientists have developed new potential therapies that selectively remove aggregated tau proteins, which are associated with Alzheimer's disease, and improve symptoms of neurodegeneration in mice.
Innovative treatments using TRIM21 have successfully targeted tau aggregates in Alzheimer’s, showing potential for broader ...
An international team of researchers has made a significant breakthrough in Alzheimer's drug development with the ...
RESEARCHERS have developed a drug that successfully blocks two major Alzheimer’s disease “hotspots” at once, in a “promising” breakthrough against the brain robbing ...
Researchers at Indiana University School of Medicine are examining the brains of individuals with asymptomatic Alzheimer's ...
In a promising breakthrough, an international team of researchers from the UK, US, and Japan has developed a new Alzheimer's ...
“Our discovery of RORB for these selectively vulnerable cells gives us the opportunity to study in detail exactly why they ...
The same team, working across the UK DRI and MRC LMB, demonstrated in 2023 that TRIM21 could be re-purposed to destroy tau protein aggregates associated with Alzheimer's disease. By switching out ...